Vimarsana
Biggest News Aggregation in the World

Page 2 - Updated Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Updated Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Updated Analysis Today - Breaking & Trending Today

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma - Vimarsana News

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting - Vimarsana News

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Soci - Vimarsana News

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Soci

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib (MK-1026) – as well as KEYTRUDA® (pembrolizumab) in multiple blood cancersRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Ca...

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting - Vimarsana News

Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting

01.12.2022 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology (ASH) Annual Meeting from Dec. ...

QBS Canada Announces Independent Study Confirming Benefits - Vimarsana News

QBS Canada Announces Independent Study Confirming Benefits

Significant Potential for Financial Saving and Better Outcomes with A Subtle Shift in the Procurement Process...